VA-REGULA
15.2.2024 08:01:33 CET | Business Wire | Press release
Frost & Sullivan recognizes companies with Best Practices Awards in various categories for outstanding efforts to inspire growth in their industries. Businesses that earn these awards identify emerging trends before they become the market standard and create solutions that drive differentiation and sustainable growth. Frost & Sullivan considers these companies to be the game changers.
As for the Enabling Technology Leadership Award in the identity verification (IDV) industry, Frost & Sullivan applies a rigorous analytical process to assess multiple nominees. This involves a detailed evaluation of best practices criteria across two dimensions: Technology Leverage and Customer Impact. Frost & Sullivan points out that Regula excels in many of the criteria in the IDV solutions space.
Synergizing cutting-edge verification technologies with an intuitive user-centric design. Experts emphasize Regula's product portfolio, seamlessly integrating a single-vendor solution for complete identity verification based on biometric (Regula Face SDK) and document (Regula Document Reader SDK) checks with enhanced authenticity validation, along with forensic devices dedicated to in-depth examination. At the heart of Regula’s IDV solution lies the most comprehensive database encompassing over 13,500 documents from 247 countries and territories, supporting over 138 languages.
Regula distinguishes itself by fostering innovation through in-house development of all technologies, steering clear of third-party dependencies. Notably, its standout feature is the platform-agnostic nature of its digital identification solutions. This enables customers to orchestrate an enhanced ID verification process effortlessly on any platform—be it mobile, web, desktop platforms, or passport readers.
Forging strategic alliances with renowned international organizations. Regula forges strategic partnerships with esteemed organizations like the International Air Transport Association, International Organization for Migration, and International Civil Aviation Organization. This collaborative effort establishes Regula as an integral player in a symbiotic exchange of insights and vital information about documents. This ongoing collaboration serves as a catalyst for continuously refining its technologies, positioning the company at the forefront of innovation.
Transforming customer workflows in many industries through value-driven verification solutions. Regula's distinctive offering lies in its rich heritage in the forensics space. The one-stop-shop nature of Regula’s solutions eradicates the necessity for customers to enlist multiple vendors for additional security measures and ensures a comprehensive strategy addressing security, forensics, and identity verification requirements in a seamless and integrated manner.
Enduring excellence through long-term customer relationships. Regula’s value-driven identity verification solutions extend across a spectrum of industry verticals, including banking, fintech, aviation, telecommunication, government authorities, healthcare, insurance, forensic labs, gambling, and others. The company's achievements are evidenced by providing hardware and software solutions for digital identity verification to a global network of over 1,000 organizations and 80 border control authorities. Notably, Regula's clientele includes major players such as the largest private bank globally, and prominent airline companies like AirAsia and WizzAir. Also, Regula has solidified its position as a trusted technology partner for several years at the Mobile World Congress (MWC), a premier international industry event organized by the GSMA.
On top of this, Frost & Sullivan believes Regula outperforms in responding to the complex landscape of identity fraud. Rabin Dhakal, Frost & Sullivan Best Practices Research Analyst states: “In the face of an escalating wave of sophisticated fraud, identity theft, and scams, the urgency for a robust identity verification solution has never been more pronounced. Frost & Sullivan believes that Regula’s proactive response to the evolving landscape of document fraud and fakes is unprecedented.”
"We are truly honored to be acknowledged by a prominent expert in market growth and innovations. We strive to emphasize the key differentiator for Regula, which lies in the wealth of experience gained over three decades - specifically in understanding documents and verification processes, our comprehensive document template database, full-cycle in-house production, and the team of top-notch forensic experts. These are the assets that enable us to drive continuous innovation and provide a comprehensive solution to identity verification,” says Ihar Kliashchou, Chief Technology Officer at Regula.
To learn more about the 2024 Frost & Sullivan Global Enabling Technology Leadership Award in the identity verification solutions industry, please read the report.
About Frost & Sullivan
Frost & Sullivan is the Growth Pipeline Company™. We power our clients to a future shaped by growth. Our Growth Pipeline as a Service™ provides the CEO and the CEO's growth team with a continuous and rigorous platform of growth opportunities, ensuring long-term success. To achieve positive outcomes, our team leverages over 60 years of experience, coaching organizations of all types and sizes across 6 continents with our proven best practices. To power your Growth Pipeline future, visit Frost & Sullivan at http://www.frost.com.
About Regula
Regula is a global developer of forensic devices and identity verification solutions. With our 30+ years of experience in forensic research and the largest library of document templates in the world, we create breakthrough technologies in document and biometric verification. Our hardware and software solutions allow over 1,000 organizations and 80 border control authorities globally to provide top-notch client service without compromising safety, security or speed. Regula was repeatedly named a Representative Vendor in Gartner® Market Guide for Identity Verification.
Learn more at www.regulaforensics.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240214825831/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From AI to Autonomous Networks: Mobileum Spark Highlights the Next Frontier of Telecom Intelligence15.10.2026 09:00:00 CEST | Press release
Industry leaders get together to explore how trusted AI, Agentic Intelligence and automation are transforming risk management, accelerating autonomous network operations and unlocking new opportunities for value creation Mobileum Inc. ("Mobileum"), a leading global provider of telecom analytics and network solutions, brought together telecom operators and industry leaders during its Mobileum Spark events series in Lisbon (Portugal) and Frankfurt (Germany), to explore how Artificial Intelligence (AI), Agentic AI and automation are transforming network operations and accelerating the evolution toward autonomous networks. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261015172815/en/ Telecom operators, industry leaders, and Mobileum experts at Mobileum Spark 2026. Focused on Risk Management & Fraud Prevention and Network Testing & Assurance, the events featured customer-led discussions, expert insights, and real-world use case
Merz Therapeutics Announces Completion of Recruitment in Two Phase III Trials Investigating XEOMIN® (incobotulinumtoxinA) for Migraine Prevention15.10.2026 08:00:00 CEST | Press release
Patient recruitment completed six months ahead of schedule in two global Phase III trials for migraine prevention MINT-E and MINT-C are evaluating XEOMIN® (incobotulinumtoxinA) for the preventive treatment of episodic and chronic migraine Trials recruited approximately 1,800 adults across 109 study sites in North America and Europe Merz Therapeutics GmbH, a leading player in neurology-focused specialty pharma, today announced the completion of patient recruitment in two global Phase III clinical trials, MINT-E (NCT07018700) and MINT-C (NCT07018713), evaluating the efficacy and safety of XEOMIN® (incobotulinumtoxinA) for the prevention of episodic and chronic migraine in adults. The trials recruited approximately 1800 adults across 109 study sites in North America and Europe. Migraine affects around 1.1 billion people worldwide, posing a significant burden on patients, society and healthcare systems.1 Both trials are evaluating the change in monthly migraine days from baseline to Month
Tourism Malaysia and Alipay+ Partner to Accelerate Malaysia’s Digital Tourism Transformation15.10.2026 07:10:00 CEST | Press release
Collaboration will connect seamless payments, in-app digital engagement and AI-powered travel services to enhance the visitor journey, empower businesses of all sizes and unlock wider cross-border commerce opportunities Tourism Malaysia and Alipay+, the unified wallet gateway of Ant International, today signed a Memorandum of Understanding (MoU) to accelerate cross-border commerce and digitalise merchant engagement across Malaysia's tourism economy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261014035900/en/ (From left) Mr Mohd Akbal Setia (Head of VM2026 Secretariat and Senior Director, Advertising & Digital Tourism); Mr Mohd Amirul Rizal Abdul Rahim (Director General, Tourism Malaysia); Mr Danny Chung (General Manager of Alipay+ Global Growth Center and Vice President of Ant International); Mr Michael Guo, Alipay+ General Manager of SEA, South Asia and ANZ, Ant International) As Malaysia welcomes visitors for Visit Mal
PeDRA 2026: Nemolizumab Phase II Data Show Long-Term Symptom Relief for Children Aged 2 to 11 Years With Moderate-to-Severe Atopic Dermatitis15.10.2026 07:00:00 CEST | Press release
Patient-reported outcomes from a phase II study of nemolizumab in children aged 2 to 11 with moderate-to-severe atopic dermatitis show meaningful reductions in itch severity, better sleep and improved quality of life, maintained for a year1 Currently, there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis, despite the high unmet need – the disease can significantly reduce quality of life for children and create burden on their families2-8 These findings expand on the clinical evidence base for nemolizumab, which has multiple global approvals for adult and pediatric patients 12 years of age and older with moderate-to-severe atopic dermatitis, and adults with prurigo nodularis9,10 Galderma (SIX: GALD), the pure-play dermatology category leader, today announced new phase II data showing that nemolizumab provided meaningful improvements in itch, sleep disturbance, and quality of life in children aged 2 to 11 years with moderate-to-severe
Takeda’s ORZEYFUL (oveporexton) Launches Simultaneously in Japan and China Giving Physicians First Access to Prescribe Novel Orexin Agonist to Patients with Narcolepsy Type 115.10.2026 02:30:00 CEST | Press release
− ORZEYFUL is now available in Japan and China following approvals within a month of each other by China’s National Medical Products Administration (NMPA), the U.S. Food and Drug Administration (FDA) and Japan’s Ministry of Health, Labour and Welfare (MHLW) − Discovered by Takeda scientists in Japan, ORZEYFUL is the lead medicine in Takeda’s orexin franchise, with multiple programs for sleep-wake disorders and conditions where orexin biology plays a role − ORZEYFUL set to launch next month in the U.S., following completion of DEA scheduling; Health Authority submissions underway worldwide Takeda (TSE:4502/NYSE:TAK)announced today that ORZEYFUL (oveporexton) is now available in Japan and China for the treatment of narcolepsy type 1 (NT1), providing first access to clinicians to prescribe treatment with the new class of medicine. ORZEYFUL is a first-in-class orexin receptor 2 (OX2R) agonist, in tablet form, designed to treat the underlying orexin deficiency associated with NT1. “We’re ex
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
